SCHEMBL1352808

SCHEMBL1352808

NCc1cccc(N)c1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNMT P11086 3/20 0.46
CD44 P16070 1/20 0.44
DPP4 P27487 2/20 0.39
CYP3A4 P08684 4/20 0.39
TSHR P16473 3/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALOX15 P16050 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
AOC1 P19801 2/20 0.38
AOC3 Q16853 2/20 0.38
LOXL2 Q9Y4K0 2/20 0.38
PIK3CA P42336 1/20 0.38
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3482721 0.81 CD44 (0.46) PNMTCD44CYP3A4TSHRALDH1A1
SCHEMBL3132841 0.81 CD44 (0.46) PNMTCD44CYP3A4TSHRALDH1A1
SCHEMBL4640275 0.80 TAAR1 (0.52) CD44SMN1; SMN2LOXL2SLC6A4
SCHEMBL3793229 0.80 ALDH1A1 (0.54) PNMTDPP4CYP3A4ALDH1A1HPGD
SCHEMBL32668885 0.78
SCHEMBL307921 0.78
SCHEMBL961729 0.77 PNMT (0.44) PNMTDPP4CYP3A4TSHRALDH1A1
SCHEMBL9112112 0.77 CD44 (0.42) CD44CYP3A4TSHRALDH1A1HPGD
SCHEMBL10285838 0.77 CD44 (0.42) PNMTCD44CYP3A4TSHRALDH1A1
SCHEMBL5591177 0.77 PNMT (0.62) PNMTDPP4CYP3A4TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9023857-B2 Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2015-05-05 US disclosed
EP-2391626-B1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS Univerzita Palackého v Olomouci (CZ) 2014-10-01 EP disclosed
US-20110287111-A1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS UNIVERZITA PALACKEHO V OLOMOUCI (CZ) 2011-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110287111-A1 SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS CDK6, CCNI, CDK2 PNMT 885/4885CD44 4815/4885DPP4 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.